253 related articles for article (PubMed ID: 17995925)
1. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats.
Yamagishi S; Ogasawara S; Mizukami H; Yajima N; Wada R; Sugawara A; Yagihashi S
J Neurochem; 2008 Jan; 104(2):491-9. PubMed ID: 17995925
[TBL] [Abstract][Full Text] [Related]
2. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
[TBL] [Abstract][Full Text] [Related]
3. The effect of pioglitazone on the liver of streptozotocin-induced diabetic albino Wistar rats.
El Gawly HW; Tawfik MK; Rashwan ME; Baruzaig AS
Eur Rev Med Pharmacol Sci; 2009; 13(6):443-51. PubMed ID: 20085125
[TBL] [Abstract][Full Text] [Related]
4. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.
Ghanaat-Pour H; Sjöholm A
Diabetes Metab Res Rev; 2009 Feb; 25(2):163-84. PubMed ID: 19065603
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
7. Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats.
Lahiri S; Sen T; Palit G
Eur J Pharmacol; 2009 May; 609(1-3):118-25. PubMed ID: 19281808
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats.
Matsumoto T; Noguchi E; Kobayashi T; Kamata K
Free Radic Biol Med; 2007 Apr; 42(7):993-1007. PubMed ID: 17349927
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.
Li L; Gao PJ; Xi R; Wu CF; Zhu DL; Yan J; Lu GP
Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1471-6. PubMed ID: 18759864
[TBL] [Abstract][Full Text] [Related]
10. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
Muranaka K; Yanagi Y; Tamaki Y; Usui T; Kubota N; Iriyama A; Terauchi Y; Kadowaki T; Araie M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4547-52. PubMed ID: 17003451
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Gad MZ; Ehssan NA; Ghiet MH; Wahman LF
Pak J Pharm Sci; 2010 Jul; 23(3):305-12. PubMed ID: 20566445
[TBL] [Abstract][Full Text] [Related]
12. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.
Pelzer T; Jazbutyte V; Arias-Loza PA; Segerer S; Lichtenwald M; Law MP; Schäfers M; Ertl G; Neyses L
Biochem Biophys Res Commun; 2005 Apr; 329(2):726-32. PubMed ID: 15737646
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
[TBL] [Abstract][Full Text] [Related]
16. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation.
Li D; Chen K; Sinha N; Zhang X; Wang Y; Sinha AK; Romeo F; Mehta JL
Cardiovasc Res; 2005 Mar; 65(4):907-12. PubMed ID: 15721871
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
Oliveira AC; Bertollo CM; Rocha LT; Nascimento EB; Costa KA; Coelho MM
Eur J Pharmacol; 2007 Apr; 561(1-3):194-201. PubMed ID: 17343847
[TBL] [Abstract][Full Text] [Related]
18. The roles of Kruppel-like factor 6 and peroxisome proliferator-activated receptor-γ in the regulation of macrophage inflammatory protein-3α at early onset of diabetes.
Qi W; Holian J; Tan CY; Kelly DJ; Chen XM; Pollock CA
Int J Biochem Cell Biol; 2011 Mar; 43(3):383-92. PubMed ID: 21109018
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice.
Huang PH; Sata M; Nishimatsu H; Sumi M; Hirata Y; Nagai R
Biomed Pharmacother; 2008 Jan; 62(1):46-52. PubMed ID: 17692499
[TBL] [Abstract][Full Text] [Related]
20. Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
Achanzar WE; Moyer CF; Marthaler LT; Gullo R; Chen SJ; French MH; Watson LM; Rhodes JW; Kozlosky JC; White MR; Foster WR; Burgun JJ; Car BD; Cosma GN; Dominick MA
Toxicol Appl Pharmacol; 2007 Sep; 223(3):246-56. PubMed ID: 17663016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]